Stay updated with breaking news from Xencor inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Thursday, RTT News reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $36.00. Wedbush’s price objective points to a potential upside […] ....
Primecap Management Co. CA lifted its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,901,607 shares of the biopharmaceutical company’s stock after acquiring an additional 717,401 shares during the […] ....
The Appeals Review Panel's In Re Xencor Decision: The USPTO Provides Its Position On Written Description And Means-Plus-Function Claims marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies | Morgan Lewis jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
United States - Patent - The Appeals Review Panel's In Re Xencor Decision: The USPTO Provides Its Position On Written Description And Means-Plus-Function Claims mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.